{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00813969",
      "OrgStudyIdInfo": {
        "OrgStudyId": "MS-MSC-001"
      },
      "Organization": {
        "OrgFullName": "The Cleveland Clinic",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS",
      "OfficialTitle": "A Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in Patients With Relapsing Forms of Multiple Sclerosis"
    },
    "StatusModule": {
      "StatusVerifiedDate": "March 2016",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 2011"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "January 2014",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "May 2014",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "December 22, 2008",
      "StudyFirstSubmitQCDate": "December 22, 2008",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "December 23, 2008",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "March 28, 2016",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "March 30, 2016",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "The Cleveland Clinic",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "University Hospitals Cleveland Medical Center",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The study is an investigator-run, open-label Phase 1 safety study of autologous mesenchymal stem cell transplantation, involving approximately 24 ambulatory participants with relapsing forms of MS (approximately equal numbers with relapsing-remitting and secondary progressive/ progressive relapsing MS) and evidence of involvement of the anterior afferent visual system."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Relapsing-Remitting Multiple Sclerosis",
          "Secondary Progressive Multiple Sclerosis",
          "Progressive Relapsing Multiple Sclerosis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Mesenchymal Stem Cell",
          "MSC",
          "Autologous",
          "Multiple Sclerosis"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "24",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Autologous MSC transplantation",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Autologous mesenchymal stem cell transplantation"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Autologous mesenchymal stem cell transplantation",
            "InterventionDescription": "A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Autologous MSC transplantation"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "To evaluate the feasibility of culturing MSCs, and infusion-related safety and tolerability of autologous MSC transplantation over one month in patients with relapsing forms of MS",
            "PrimaryOutcomeTimeFrame": "1 month"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "To evaluate effects on MS disease activity measured by the number of Gd-enhancing brain MRI lesions",
            "SecondaryOutcomeTimeFrame": "1 month"
          },
          {
            "SecondaryOutcomeMeasure": "To evaluate safety and tolerability of autologous MSC transplantation over 6 months",
            "SecondaryOutcomeTimeFrame": "6 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAge 18 to 55, inclusive.\nDiagnosis of MS\nRelapsing form of MS (relapsing-remitting, secondary progressive, or progressive-relapsing course).\nEDSS score 3.0-6.5, inclusive. (Must be able to walk)\nActive disease during prior 24 months.\nDocumented evidence of involvement of the anterior afferent visual system: previous optic neuritis, optic atrophy or an afferent pupillary defect on exam, RNFL thickness on OCT <LLN in at least one eye OR documented VEP latency in at least 1 eye.\nCranial MRI scan demonstrating T2-hyperintense lesions satisfying diagnostic criteria for MS\nAbility to perform the component tests of the MSFC (T25FW, 9HPT, PASAT3).\nAbility to perform SLCLA.\nHas given written informed consent to participate in the study.\n\nExclusion Criteria:\n\nA clinically significant infectious illness (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days of the Screening Visit.\nHistory of cancer other than basal cell carcinoma of the skin.\nHistory or laboratory results indicative of any significant cardiac, endocrine, hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neoplastic, or other disorder that in the opinion of the Principal Investigator would preclude the safe performance of BM aspiration, infusion of autologous MSCs, or performance of any of the planned study assessments.\nAbnormal blood tests which exceed designated limits.\nPositive screening tests for hepatitis B, hepatitis C, HIV 1&2, HTLV I/II, CMV, West Nile virus, syphilis, blood parasite infection.\nClinically significant abnormality on chest X-ray.\nClinically significant abnormality on EKG.\nOxygen-saturation <90% on room air.\nHistory of alcohol or drug abuse within one year.\nAny metallic material or electronic device in the body, or condition that precludes the participant from undergoing MRI with Gd administration.\nUncontrolled glaucoma or other ocular condition that precludes performing OCT or interpreting the results.\nMS relapse with onset within 30 days prior to the Screening Visit or the participant has not stabilized from a previous relapse at the time of the Screening Visit.\nCurrent treatment with an investigational MS disease therapy.\nPrior treatment with:\n\nTotal lymphoid irradiation. Cladribine. T-cell or T-cell receptor vaccination. Campath-1h (alemtuzumab). Rituxan (rituximab).\n\nPrior treatment within three months with:\n\nTysabri (natalizumab). Gilenya (Fingolimod/FTY720). Zenapax (daclizumab). Cytoxan (cyclophosphamide). Novantrone (mitoxantrone). Cyclosporine. CellCept (mycophenolate mofetil). Imuran (azathioprine). Rheumatrex (methotrexate). IV gamma globulin. Plasma exchange.\n\nPrior treatment within one month:\n\nSystemic corticosteroids with daily dose equivalent to Prednisone 60 mg or greater.\n\nFemale participants who are not post-menopausal for at least one year, not surgically sterile, or not willing to practice effective contraception.\nNursing mothers, pregnant women, or women planning to become pregnant during the study.\nMale participants who are not willing to practice effective contraception.\nUnwillingness or inability to comply with the requirements of this protocol including the presence of any condition (physical, mental, or social) that, in the opinion of the Principal Investigator, is likely to affect the participant's ability to comply with the study protocol.\nAny other reason that, in the opinion of the Principal Investigator, makes the participant unsuitable for participation in the study.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "55 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Jeffrey A Cohen, M.D.",
            "OverallOfficialAffiliation": "The Cleveland Clinic",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Cleveland Clinic Mellen Center",
            "LocationCity": "Cleveland",
            "LocationState": "Ohio",
            "LocationZip": "44195",
            "LocationCountry": "United States"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "28381130",
            "ReferenceType": "derived",
            "ReferenceCitation": "Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M, Morrison S, Reese Koc J, Gerson SL, Lazarus HM. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Scler. 2018 Apr;24(4):501-511. doi: 10.1177/1352458517703802. Epub 2017 Apr 6."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009103",
            "ConditionMeshTerm": "Multiple Sclerosis"
          },
          {
            "ConditionMeshId": "D000020529",
            "ConditionMeshTerm": "Multiple Sclerosis, Relapsing-Remitting"
          },
          {
            "ConditionMeshId": "D000020528",
            "ConditionMeshTerm": "Multiple Sclerosis, Chronic Progressive"
          },
          {
            "ConditionMeshId": "D000012598",
            "ConditionMeshTerm": "Sclerosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000020278",
            "ConditionAncestorTerm": "Demyelinating Autoimmune Diseases, CNS"
          },
          {
            "ConditionAncestorId": "D000020274",
            "ConditionAncestorTerm": "Autoimmune Diseases of the Nervous System"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000003711",
            "ConditionAncestorTerm": "Demyelinating Diseases"
          },
          {
            "ConditionAncestorId": "D000001327",
            "ConditionAncestorTerm": "Autoimmune Diseases"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11212",
            "ConditionBrowseLeafName": "Multiple Sclerosis",
            "ConditionBrowseLeafAsFound": "Multiple Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14567",
            "ConditionBrowseLeafName": "Sclerosis",
            "ConditionBrowseLeafAsFound": "Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11459",
            "ConditionBrowseLeafName": "Neoplasm Metastasis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21467",
            "ConditionBrowseLeafName": "Multiple Sclerosis, Relapsing-Remitting",
            "ConditionBrowseLeafAsFound": "Relapsing Remitting Multiple Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21466",
            "ConditionBrowseLeafName": "Multiple Sclerosis, Chronic Progressive",
            "ConditionBrowseLeafAsFound": "Secondary Progressive Multiple Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3781",
            "ConditionBrowseLeafName": "Autoimmune Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21251",
            "ConditionBrowseLeafName": "Demyelinating Autoimmune Diseases, CNS",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21247",
            "ConditionBrowseLeafName": "Autoimmune Diseases of the Nervous System",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6061",
            "ConditionBrowseLeafName": "Demyelinating Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          }
        ]
      }
    }
  }
}